TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17445634

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (125 mg) every 8 hours (maximum of 21 doses)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15064295

Group type: EXPERIMENTAL
Intervention: Triage-based e-mail system
Number of subjects: 3007
Study: 19759966

Group type: EXPERIMENTAL
Intervention: Energy conservation training (1 to 2 hours of individual training followed by weekly telephone monitoring for 3 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual care control (standard care from oncologist)
Number of subjects: 12
Study: 10555027

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) 2000 mg/day
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study: 8707971

Group type: EXPERIMENTAL
Intervention: Active prescale gel
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active prescale gel (extended exposure)
Number of subjects: 10
Study: 1762068

Group type: EXPERIMENTAL
Intervention: 3.75 mg of morphine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 7.5 mg of morphine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 15 mg of morphine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 30 mg of morphine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lowest dose of morphine (not specified)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intermediate doses of morphine (not specified)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Highest dose of morphine (30 mg)
Number of subjects: 5
Study: 6347229

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoprolol SA 200 mg once daily
Number of subjects: 20
Study: 31389784

Group type: EXPERIMENTAL
Intervention: methyl‐5‐aminolevulinate 16% cream-Photodynamic therapy (PDT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: imiquimod 5% cream
Number of subjects: 10
Study: 29739371

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation (Rehab, n = 43)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Progressive exercises (Physio, n = 43)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Self-care advice (Advice, n = 40)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 193
Study: 27352310

Group type: EXPERIMENTAL
Intervention: Baicalein 200 mg once daily on days 1 and 10, twice daily on days 3-9
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Baicalein 400 mg once daily on days 1 and 10, twice daily on days 3-9
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Baicalein 800 mg once daily on days 1 and 10, twice daily on days 3-9
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 24827888

Group type: EXPERIMENTAL
Intervention: Red grape cells (RGC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RGC-derived resveratrol (RES)
Number of subjects: 0
Study: 22958313

Group type: EXPERIMENTAL
Intervention: Stern‐E‐Fix corset postoperatively for 6 weeks
Number of subjects: 750

Group type: COMPARATOR
Intervention: Standard elastic thorax bandage
Number of subjects: 750
Study: 20925995

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham (placebo) ultrasound
Number of subjects: 90
Study: 18403402

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 425

Group type: COMPARATOR
Intervention: Mock TENS (control)
Number of subjects: 425
Study: 15814399

Group type: EXPERIMENTAL
Intervention: CO2 pneumoperitoneum
Number of subjects: 145

Group type: COMPARATOR
Intervention: Room air pneumoperitoneum
Number of subjects: 145
Study: 12457671

Group type: EXPERIMENTAL
Intervention: Fentanyl (5 microg bolus doses via PCA after IV loading dose of 0.7 microg/kg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (balanced salt solution without analgesic via PCA)
Number of subjects: 68
Study: 10542999

Group type: EXPERIMENTAL
Intervention: C1-inhibitor administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8949757

Group type: EXPERIMENTAL
Intervention: twice‐daily neutron therapy for advanced head and neck cancer
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: neutron therapy for advanced salivary gland tumours
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: neutron therapy for locally advanced breast cancer
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: neutron therapy for macroscopic residual soft tissue sarcomas
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: neutron therapy for macroscopic residual uterine sarcoma
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: neutron therapy for advanced squamous carcinoma of the maxillary antrum
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: neutron therapy for advanced osteosarcomas and chondrosarcomas
Number of subjects: 721
Study: 1681558

Group type: EXPERIMENTAL
Intervention: Loprazolam 2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Loprazolam 1 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31234842

Group type: COMPARATOR
Intervention: School-located influenza vaccination (SLIV) in elementary schools
Number of subjects: 80

Group type: COMPARATOR
Intervention: School-located influenza vaccination (SLIV) in secondary schools
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) in elementary schools with spillover impact
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) in secondary schools with spillover impact
Number of subjects: 80
Study: 28261955

Group type: EXPERIMENTAL
Intervention: Beloranib 1.8 mg subcutaneously twice weekly for 4 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Beloranib 1.8 mg (after 4-week open-label extension)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Beloranib treatment
Number of subjects: 14
Study: 26344014

Group type: EXPERIMENTAL
Intervention: Resveratrol for 28 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 60
Study: 23150685

Group type: EXPERIMENTAL
Intervention: Exposure at 19 C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure at 24 C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold-induced increase in FGF21
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in area under the curve plasma FGF21 between 19 and 24 C
Number of subjects: 0
Study: 20932798

Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin solution [Mal]
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 7.1% glucose solution [Glu]
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: water [Wa]
Number of subjects: 14

Group type: COMPARATOR
Intervention: control trial with no rinse [Con]
Number of subjects: 14
Study: 19344032

Group type: EXPERIMENTAL
Intervention: Matching wide‐diameter prosthetic components (group A)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Platform‐switched prosthetic components (group B)
Number of subjects: 144
Study: 16464289

Group type: EXPERIMENTAL
Intervention: Children with OCD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adolescents and adults with OCD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All age groups (children, adolescents, adults)
Number of subjects: 0
Study: 15023579

Group type: EXPERIMENTAL
Intervention: Increased orbitofrontal cortex to amygdala ratio (OAR) in men with schizophrenia
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Decreased orbitofrontal cortex to amygdala ratio (OAR) in women with schizophrenia
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Increased OAR in men
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Decreased OAR in women
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Increased amygdala volume in men
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Higher volumes of both amygdala and orbitofrontal regions in women
Number of subjects: 111
Study: 11316092

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% and Timolol 0.5%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9399007

Group type: EXPERIMENTAL
Intervention: Primary headache sufferers (MO, MA, TH)
Number of subjects: 430
Study: 7653736

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Cetirizine 2.5 mg
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 3300580

Group type: EXPERIMENTAL
Intervention: Cefamandole (CM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefazolin (CZ)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vancomycin (V)
Number of subjects: 20
Study: 31441852

Group type: EXPERIMENTAL
Intervention: Group A (continuous infusion with 0.01 mg/kg/h and a bolus dose with 0.03 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group B (a bolus dose with 0.03 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group C (PCA administered as a time‐scheduled decremental continuous infusion based on lean body mass)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 90
Study: 29112754

Group type: EXPERIMENTAL
Intervention: Goal of 'never smoke again'
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Goal of 'taking it a cigarette at a time'
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Goal of 'seeing how it will go'
Number of subjects: 1043
Study: 25130962

Group type: EXPERIMENTAL
Intervention: Counselors who received a summary of the questionnaire results prior to the telephone session
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Telephone session with feedback on psychosocial problems
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Routine extension of the CGCT procedure
Number of subjects: 118
Study: 23532477

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 328
Study: 21912321

Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty (BKP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard medical treatment (control)
Number of subjects: 63
Study: 19781402

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 270
Study: 16962938

Group type: EXPERIMENTAL
Intervention: High phenolic content virgin olive oil (25 ml/day for 3 weeks)
Number of subjects: 28
Study: 12618946

Group type: EXPERIMENTAL
Intervention: Micropuncture laparoscopic cholecystectomy (MPLC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 40
Study: 11193166

Group type: EXPERIMENTAL
Intervention: Talsaclidine (selective muscarinic M1 agonist), administered for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (control group), administered for 4 weeks
Number of subjects: 24
Study: 9076645

Group type: EXPERIMENTAL
Intervention: Estrogen implant
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo implant
Number of subjects: 40
Study: 8376594

Group type: EXPERIMENTAL
Intervention: E2348/69 EPEC strain (wild-type)
Number of subjects: 11

Group type: COMPARATOR
Intervention: eaeA deletion mutant
Number of subjects: 11
Study: 3790956

Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g IV/8 h for 2 days)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Metronidazole (1 g IV on induction and 12 h postoperatively)
Number of subjects: 226
Study: 30012018

Group type: EXPERIMENTAL
Intervention: Hand-washing education or promotional materials
Number of subjects: 222599

Group type: COMPARATOR
Intervention: Control group (no hand-washing education or promotional materials)
Number of subjects: 222599
Study: 27734319

Group type: EXPERIMENTAL
Intervention: MMI plus selenium
Number of subjects: 30

Group type: COMPARATOR
Intervention: MMI
Number of subjects: 30
Study: 25292280

Group type: EXPERIMENTAL
Intervention: Plain cigarette packs
Number of subjects: 144

Group type: COMPARATOR
Intervention: Branded cigarette packs
Number of subjects: 144

Group type: COMPARATOR
Intervention: No-stimulus condition
Number of subjects: 144

Group type: COMPARATOR
Intervention: Plain cigarette packs vs Branded cigarette packs
Number of subjects: 144

Group type: COMPARATOR
Intervention: Plain cigarette packs vs No-stimulus condition
Number of subjects: 144
Study: 23011911

Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT) with concurrent 5-fluorouracil/mitomycin C
Number of subjects: 292
Study: 21736599

Group type: EXPERIMENTAL
Intervention: Subgingival debridement by glycine powder/air polishing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ultrasonic instrumentation
Number of subjects: 20
Study: 20110036

Group type: EXPERIMENTAL
Intervention: CIC‐AQ 300 microg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CIC‐HFA 300 microg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CIC HFA‐MDI 320 microg
Number of subjects: 30

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 30
Study: 16422140

Group type: EXPERIMENTAL
Intervention: Stage-matched intervention
Number of subjects: 208

Group type: COMPARATOR
Intervention: Social-cognitive intervention
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 208
Study: 15521216

Group type: EXPERIMENTAL
Intervention: Ozonated autohemotherapy (O3‐AHT) with ozone concentration of 50 microg/ml
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo-control (autohemotherapy without ozone exposure)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Baseline measurement
Number of subjects: 12
Study: 11463111

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 219

Group type: COMPARATOR
Intervention: mefloquine-artesunate
Number of subjects: 219
Study: 9726386

Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole/day
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine/day
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Termination of therapy
Number of subjects: 114
Study: 8027291

Group type: EXPERIMENTAL
Intervention: 0.5 ml insemination
Number of subjects: 177

Group type: COMPARATOR
Intervention: 0.25 ml insemination
Number of subjects: 177
Study: 2572101

Group type: EXPERIMENTAL
Intervention: Topical treatment with MC 903 (new synthetic vitamin D3 analogue)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 5
Study: 1178407

Group type: EXPERIMENTAL
Intervention: Red illumination
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Yellow illumination
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blue illumination
Number of subjects: 40

Group type: COMPARATOR
Intervention: Green illumination
Number of subjects: 40
Study: 29486765

Group type: EXPERIMENTAL
Intervention: Xiangbin prescription (XBP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26272266

Group type: EXPERIMENTAL
Intervention: 1% tannin green tea mouthwash
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 40
Study: 26263802

Group type: EXPERIMENTAL
Intervention: Primary repair of GHH via laparoscopic surgery (95% completed, mesh in 6%, Collis gastroplasty in 7%)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Primary repair of GHH
Number of subjects: 455
Study: 23893178

Group type: EXPERIMENTAL
Intervention: Ziprasidone (complete substitution)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Combined treatment (partial substitution)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control (TESS score)
Number of subjects: 194
Study: 21918156

Group type: EXPERIMENTAL
Intervention: Pentax AWS video laryngoscope
Number of subjects: 105

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (using a #4 blade)
Number of subjects: 105
Study: 18770102

Group type: EXPERIMENTAL
Intervention: APPN-PCP collaborative model including pharmacological and psychosocial interventions
Number of subjects: 41
Study: 17154779

Group type: EXPERIMENTAL
Intervention: High-level motion perception (top-down processes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical motion stimulus (when direction was not identified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive, preattentive mechanism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top-down process (perceptual awareness of motion direction)
Number of subjects: 0
Study: 12669883

Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: AH 26
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pulp Canal Sealer
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ketac-Endo
Number of subjects: 48
Study: 11129742

Group type: EXPERIMENTAL
Intervention: T'ai Chi training (two 1-hour classes per week for 12 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 33
Study: 9183321

Group type: EXPERIMENTAL
Intervention: Wheat starch-containing product (4 to 6 portions daily for up to 1 year)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Wheat starch-containing product
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (patients with celiac disease who tolerated wheat starch)
Number of subjects: 17
Study: 1359096

Group type: EXPERIMENTAL
Intervention: 1% tropicamide micro drops
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard size drops (1% tropicamide and 10% phenylephrine)
Number of subjects: 20
Study: 3887974

Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 10
Study: 31130959

Group type: EXPERIMENTAL
Intervention: Glucocorticosteroids and/or adjuvant immunosuppressive drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel treatment targets
Number of subjects: 0
Study: 29781648

Group type: EXPERIMENTAL
Intervention: Guided ICBT via smartphone app
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Guided ICBT via PC
Number of subjects: 150

Group type: COMPARATOR
Intervention: Wait list control (WL)
Number of subjects: 150
Study: 27459535

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 60
Study: 24625392

Group type: EXPERIMENTAL
Intervention: α-synuclein levels in cerebrospinal fluid
Number of subjects: 300
Study: 23867622

Group type: EXPERIMENTAL
Intervention: Daily 2-hour cold exposure at 17°C for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily ingestion of capsinoids for 6 weeks
Number of subjects: 0
Study: 20106601

Group type: EXPERIMENTAL
Intervention: Unobserved induction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Observed induction
Number of subjects: 20
Study: 18382005

Group type: EXPERIMENTAL
Intervention: Peer-mentoring behavioral intervention
Number of subjects: 418

Group type: COMPARATOR
Intervention: Control group (time-equivalent attention-control)
Number of subjects: 418
Study: 16361874

Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT) for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study: 12790259

Group type: EXPERIMENTAL
Intervention: Cancer education
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Emotional expression
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 222
Study: 10756964

Group type: EXPERIMENTAL
Intervention: Water-free lithium hydroxide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Moist Drägersorb 800
Number of subjects: 16
Study: 8968170

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg orally 2 h before induction and an infusion of 0.1 mg.kg‐1.h‐1 for 23 h)
Number of subjects: 30
Study: 1477874

Group type: EXPERIMENTAL
Intervention: artemether (n = 24), 9.6 mg/kg body weight intramuscularly over five days
Number of subjects: 47

Group type: COMPARATOR
Intervention: chloroquine (n = 23), 25 mg/kg body weight orally
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: artemether
Number of subjects: 47

Group type: COMPARATOR
Intervention: chloroquine
Number of subjects: 47
Study: 3511402

Group type: EXPERIMENTAL
Intervention: Progabide (32 mg/kg mean daily dose, range 16 to 63)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Progabide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31900018

Group type: EXPERIMENTAL
Intervention: Value reference points
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Risk preference
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Knowledge of hypertension, expectation, health literacy, opportunity costs
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Certainty effect, overconfidence, optimism
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Health education and better health service resources
Number of subjects: 321
Study: 30205906

Group type: EXPERIMENTAL
Intervention: Remifentanil–ketamine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Propofol–ketamine
Number of subjects: 70
Study: 27294271

Group type: EXPERIMENTAL
Intervention: AERLI educational intervention (face-to-face educational session)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Standard harm reduction centers (without intervention)
Number of subjects: 271
Study: 23799806

Group type: EXPERIMENTAL
Intervention: EPPM-based training curriculum
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (randomly assigned)
Number of subjects: 71
Study: 22082089

Group type: EXPERIMENTAL
Intervention: PROMETA Protocol (flumazenil 2 mg infusions on days 1, 2, 3, 22, 23; gabapentin 1200 mg to day 40; hydroxazine 50 mg to day 10)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo medication (with active hydroxazine only)
Number of subjects: 120
Study: 20123357

Group type: EXPERIMENTAL
Intervention: Assessment of molecular biomarkers in surgical UCB specimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular biomarkers
Number of subjects: 0
Study: 18721246

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 2998

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2998